Abstract
Fluconazole (FLCZ) is an azole antifungal agent and it has shown excellent clinical activities in suppressing fungemia with Candida albicans after hematopoietic stem cell transplantation. Increased administration of prophylactic FLCZ seems to have given rise to the relatively higher incidence of more resistant Candida non-albicans infection. We present a case with a rare breakthrough fungemia with C. guilliermondii after cord blood transplantation for Extranodal NK cell Lymphoma, nasal type (ENKL), during antifungal prophylaxis with FLCZ. High level of caution is needed for the breakthrough, especially after long-term azole administration.
Keywords:
Candida guilliermondii; breakthrough; cord blood transplantation; extranodal NK cell lymphoma; fluconazole.
© 2018 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
MeSH terms
-
Adult
-
Antibiotic Prophylaxis / adverse effects*
-
Antifungal Agents / therapeutic use*
-
Candida / drug effects
-
Candida / isolation & purification
-
Candida / physiology*
-
Candidemia / complications
-
Candidemia / drug therapy*
-
Candidemia / microbiology
-
Candidemia / prevention & control
-
Candidiasis, Invasive / complications
-
Candidiasis, Invasive / drug therapy*
-
Candidiasis, Invasive / microbiology
-
Candidiasis, Invasive / prevention & control
-
Cord Blood Stem Cell Transplantation / adverse effects*
-
Drug Resistance, Multiple, Fungal / drug effects
-
Female
-
Fluconazole / adverse effects
-
Humans
-
Lymphoma, Extranodal NK-T-Cell / surgery*
-
Microbial Sensitivity Tests
-
Pregnancy
-
Pregnancy Complications, Infectious / drug therapy*
-
Pregnancy Complications, Infectious / microbiology
-
Pregnancy Complications, Infectious / prevention & control
-
Stillbirth
-
Young Adult
Substances
-
Antifungal Agents
-
Fluconazole